Namita Mitra

Namita Mitra

BVSc Veterinary Sciences, MVSc Veterinary Microbiology, PhD Animal Biotechnology, ACVM Diplomate-Virology

After earning a bachelor’s degree in Veterinary Sciences and Animal Health  (BVSc) in 2007, Namita went on to pursue a Master of Veterinary Microbiology from GADVASU, India. Her Master’s research on the molecular and histopathological diagnosis of avian oncogenic viruses in poultry brought her two national awards.

See more

In 2013, she was conferred a doctoral degree in Animal Biotechnology that concluded with her research findings on expression profiling of apoptosis-associated genes in canine mammary tumors. Right after her graduation, Namita worked as Assistant Professor of Animal Biotechnology and taught the courses of Animal Cell Culture, Animal Genetic Engineering, and Molecular Immunology.

A year later, she moved to the USA and joined as a research assistant in the Kansas State Veterinary Diagnostic lab. There, she worked on next-generation sequencing and data analysis with an emphasis on viral metagenomics. Driven by her deep interest in virology, she studied for the ‘American College of Veterinary Microbiologists (ACVM) board exam’ and in Dec 2018,  she was awarded ACVM Virology- diplomate status by the board.

In 2019, she joined the center for genome architecture at Baylor College of Medicine, where she got the opportunity to work on two very diverse projects; one of which was focused on the development of NGS-based diagnostic for SARS-CoV-2, and the other was to understand the crucial part of CTCF transcription factor that potentially interacts with cohesin protein to form chromatin loops.

An author and co-author of many peer-reviewed articles and a reviewer herself, Namita enjoys editing and reviewing scientific documents. She is interested in science outreach to the general audience. At the same time, she intends to communicate novel scientific discoveries to researchers and academic professionals. In her spare time, she loves to read and spend time with her daughter and family.

See less

Articles from Namita Mitra

Long term vaccine response following Pfizer COVID-19 vaccination in hemodialysis patients

Long term vaccine response following Pfizer COVID-19 vaccination in hemodialysis patients

Neutralization antibodies elevated in nursing home residents after COVID-19 mRNA boosters

Neutralization antibodies elevated in nursing home residents after COVID-19 mRNA boosters

Safety and immunogenicity of SARS-CoV-2 recombinant spike protein vaccine

Safety and immunogenicity of SARS-CoV-2 recombinant spike protein vaccine

Saliva samples show better sensitivity for early stages of COVID-19 detection

Saliva samples show better sensitivity for early stages of COVID-19 detection

Modeling emergence and dynamics of new COVID-19 variants in the UK

Modeling emergence and dynamics of new COVID-19 variants in the UK

Fourth shot of Moderna COVID vaccine improves Delta variant neutralization in kidney transplant patients

Fourth shot of Moderna COVID vaccine improves Delta variant neutralization in kidney transplant patients

Identifying the spread of novel B.1.1.523 SARS-CoV-2

Identifying the spread of novel B.1.1.523 SARS-CoV-2

Similar antibody responses to spike protein in COVID-19 survivors and vaccine recipients

Similar antibody responses to spike protein in COVID-19 survivors and vaccine recipients

Increased risk of breakthrough SARS-CoV-2 infection with ChAdOx1 compared to BNT162b2 vaccine

Increased risk of breakthrough SARS-CoV-2 infection with ChAdOx1 compared to BNT162b2 vaccine

Emergence of SARS-CoV-2 immune escape variants in an immunocompromised patient

Emergence of SARS-CoV-2 immune escape variants in an immunocompromised patient

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.